Global Lisinopril market size 2025 was XX Million. Lisinopril Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

According to Cognitive Market Research, the global Angiotensin Converting Enzyme Inhibitors market size is USD 3651.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 5.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 1460.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1095.36 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 839.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Latin America had a market share for more than 5% of the global revenue with a market size of USD 184.06 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 73.02 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.
The Lisinopril held the highest Angiotensin Converting Enzyme Inhibitors market revenue share in 2024.

Market Dynamics of Angiotensin Converting Enzyme Inhibitors Market

Key Drivers for Angiotensin Converting Enzyme Inhibitors Market

Rising Prevalence of Cardiovascular Diseases (CVDs) to Increase the Demand Globally

The ACE inhibitor marketplace is propelled with the aid of the escalating occurrence of cardiovascular diseases (CVDs) internationally, along with coronary artery disease, coronary heart failure, and hypertension. This surge is, by and large, fueled by means of unhealthy lifestyles, the populace growing older, and the rising incidence of diabetes. Unchecked factors, which include poor nutritional habits, passive exercises, and strain, exacerbate the hazard factors associated with CVDs, thereby driving up the call for remedies like ACE inhibitors. As these situations turn out to be more regular globally, the marketplace for ACE inhibitors is anticipated to hold its boom trajectory in addressing the escalating burden of cardiovascular ailments.

Effective Treatment for Hypertension to Propel Market Growth

ACE inhibitors serve as frontline interventions for high blood pressure, a massive chance element for coronary heart sickness and stroke. Renowned for their efficacy in lowering blood pressure ranges, ACE inhibitors preserve prominence in medical practice. By inhibiting the angiotensin-converting enzyme, these medicinal drugs efficaciously dilate blood vessels, for this reason reducing vascular resistance and reducing blood pressure. Their dependable antihypertensive motion no longer most effectively mitigates the on-the-spot risk of cardiovascular activities; however additionally offer long-term advantages in fending off related complications. As a cornerstone of hypertension control, ACE inhibitors play an essential function in maintaining cardiovascular health and reducing morbidity and mortality rates related to high blood pressure-associated headaches like myocardial infarction and cerebrovascular injuries.

Restraint Factor for the Angiotensin Converting Enzyme Inhibitors Market

Availability of Generic Drugs to Limit the Sales

The presence of universal ACE inhibitors offers a cost-effective opportunity for sufferers, enhancing accessibility to important cardiovascular remedies. While wonderful for healthcare structures and clients, the proliferation of generic alternatives can pose demanding situations for pharmaceutical organizations investing in the improvement of novel ACE inhibitor drugs. The marketplace saturation with generics exerts pressure on income margins and return on funding for those corporations. To navigate this landscape, pharmaceutical firms may additionally need to innovate by focusing on novel formulations, mixture therapies, or area of interest markets to distinguish their products and maintain aggressive advantages. Despite the cost pressures, the provision of regular ACE inhibitors remains pivotal in ensuring sizeable affordability and adherence to hypertension management, thereby addressing public health desires effectively.

Impact of Covid-19 on the Angiotensin Converting Enzyme Inhibitors Market

The angiotensin-converting enzyme (ACE) Inhibitors market skilled vast shifts d...

In 2024, French pharmaceutical company Sanofi generated approximately ** billion euros through its biopharmaceutical segment. In 2023, Sanofi’s consumer healthcare segment earned the company about *** billion euros in that year. As of early 2025, due to several restructuring measures, Sanofi consists only of the biopharma segment. Sanofi’s top products Sanofi develops various pharmaceutical products, including Dupixent and Lantus. Lantus has been one of the company’s top products for many years. In 2024, this long-acting insulin, used to treat diabetes, generated some *** billion euros. Top U.S. drugs Based on sales numbers over the last years, Humira is by far the top prescription drug in the United States. Before 2023, the drug generated around ** billion U.S. dollars in the United States per year. Among the country’s most prescribed medicines, however, are atorvastatin, lisinopril, and levothyroxine.

Market Summary of Congestive Heart Failure Drugs Market :

• The global Congestive Heart Failure Drugs market size in 2023 was XX Million. Congestive Heart Failure Drugs Industry's compound annual growth rate (CAGR) will be XX% from 2024 to 2031. • Increase in the cases of Heart problems and advancement in technology and increase in Research and development drive the market for Heart Failure Drugs. • The ACE inhibitors medicine class is the dominating. Angiotensin-converting enzyme inhibitors, or ACE inhibitors, have been a main key in the management of congestive heart failure for several years • Market growth was significantly impacted by the COVID-19 epidemic. Heart Failure or cardiovascular medications are frequently utilized because hypertension is one of the most common symptoms among COVID-19 patients • North America is the dominant region for congestive heart failure (CHF). Congestive heart failure and other cardiovascular illnesses are rather common in North America.

Market Dynamics of Congestive Heart Failure Drugs Market:

Key Drivers of Congestive Heart Failure Drugs Market:

Increase in the cases of Heart problems, the market for Congestive heart failure drugs increases.

Heart failure is a long-term illness characterized by inadequate cardiac pumping function. If the heart is unable to pump blood sufficiently during the diastolic or systolic phases, heart failure may result. For Instance, according to the Journal of Cardiac Failure, Heart failure has affected about 6.7 million adults over the age of 20, and by 2030, that number is predicted to increase to 8.5 million. Heart failure is becoming more commonplace worldwide as a result of sedentary lifestyles, poor eating habits, and an increase in risk factors such as obesity, diabetes, and hypertension. Furthermore, according to recent data released by the British Heart Foundation (BHF), the number of early heart disease deaths in England has increased to its highest level since 2008. More than 39,000 people in England passed away too soon from cardiovascular diseases in 2022. (Source:https://onlinejcf.com/article/S1071-9164(23)00264-6/abstract#:~:text=1.,develop%20HF%20in%20their%20lifetime.)The reasons why heart failure is increasing are due to aging, family history, lifestyle choices like smoking, abusing alcohol excessively, abusing cocaine or other illegal drugs, maintaining an unhealthy diet, and not exercising. The risk is also increased by heart or blood vessel disorders, severe lung diseases, and infections like SARS-CoV-2 or HIV. Hence, Effective heart failure medications are in high demand due to the expanding patient population. Using medication to treat heart failure helps reduce edema, breathlessness, and exhaustion. Additionally, it increases the energy so one can engage in physical activity. Even in the absence of symptoms, medications can halt or reduce the disease's progression. People with heart failure may require several drugs. Each has instructions and regulations specific to it and addresses a distinct symptom or contributing cause. For Instance, An ARB and a neprilysin inhibitor are combined to form ARNIs. An enzyme called neprilysin helps the body release naturally occurring chemicals that widen constricted arteries. Reducing the impact of neprilysin enhances the benefits of these drugs, enhancing blood flow and arterial opening, lowering sodium retention, and lessening cardiac strain. (Source:https://pharmatimes.com/news/bhf-data-reveals-early-heart-disease-deaths-rise-to-highest-level/ )Hence, due to the increase in Heart failure cases due to various reasons, the drug market for the same is increasing.

Advancement in technology and increase in Research and development drive the market for Heart Failure Drugs.

Cardiovascular medications have undergone substantial R&D and technological advancements. Subsequently, several ground-breaking treatments were released onto the global market and quickly gained popularity. Nevertheless, patients' treatment options are being limited due to the increasing frequency of cardiovascular illnesses, which are almost incurable due to their nature. This has caused a significant gap in the industry's supply of treatment needs and is anticipated to be one of the main drivers for the drug development o...

Global Angiotensin Converting Enzyme ACE Inhibitors market size 2025 was XX Million. Angiotensin Converting Enzyme ACE Inhibitors Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

Global Alport Syndrome Treatment market size 2025 was XX Million. Alport Syndrome Treatment Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

Global Kidney - Renal Fibrosis market size 2025 was XX Million. Kidney - Renal Fibrosis Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

As per Cognitive Market Research's latest published report, the Global Chronic kidney disease drugs market size was $13,678.0 million in 2022. Chronic kidney disease drugs Industry's Compound Annual Growth Rate will be 4.8% from 2023 to 2030. Factors Impacting on Chronic Kidney Disease Drugs Market

The increasing prevalence of chronic kidney disease is forecasted to drive the growth of the global chronic kidney disease drug market. In addition, growing research and development activities in the development of chronic kidney disease drugs are forecasted to dominate the global market. Furthermore, government initiatives for regulatory approvals and favorable insurance policies are forecasted to provide the opportunity for the target market. However, high treatment costs and a lack of awareness about kidney disorders may hamper the growth of the market.

Introduction of Chronic Kidney Disease Drugs.

The progressive loss of kidney function in the body leads to kidney failure and this condition is known as chronic kidney disease. Chronic kidney diseases damage the kidney by building up a high level of fluid, electrolytes, and wastes in the body. This kidney disease deteriorates the function of the kidney and the kidney cannot perform its natural functions properly. The symptoms of chronic kidney disease are sleep problems, vomiting, nausea, loss of appetite, weakness, high blood pressure, and others.

According to Cognitive Market Research, the global Dilated Cardiomyopathy Market size will be USD 468.52 million in 2025. It will expand at a compound annual growth rate (CAGR) of 4.70% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 173.35 million in 2025 and will grow at a compound annual growth rate (CAGR) of 2.5% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 135.87 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 112.44 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.7% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 17.80 million in 2025 and will grow at a compound annual growth rate (CAGR) of 3.7% from 2025 to 2033.
Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 18.74 million in 2025 and will grow at a compound annual growth rate (CAGR) of 4.0% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 10.31 million in 2025 and will grow at a compound annual growth rate (CAGR) of 4.4% from 2025 to 2033.
Beta-Blockers category is the fastest growing segment of the Dilated Cardiomyopathy industry

Market Dynamics of Dilated Cardiomyopathy Market

Key Drivers for Dilated Cardiomyopathy Market

Increasing Incidence of Cardiovascular Disorders to Boost Market Growth

One of the main factors propelling the dilated cardiomyopathy (DCM) market is the increasing incidence of cardiovascular disorders. Globally, the prevalence of diseases, including diabetes, heart failure, obesity, and hypertension, is rising, which greatly contributes to the rising incidence of DCM. The World Health Organization states that heart disease continues to be the primary cause of death globally and that DCM accounts for a significant percentage of heart failure cases. This increasing burden is fueling the need for efficient diagnostic and treatment options. Additionally, new developments in diagnostic tools, including genetic testing, cardiac MRI, and echocardiography, are enhancing the early identification and detection of DCM, allowing for prompt intervention and improved disease management.

Rising Programs for Patient Education to Boost Market Growth

In the global market for dilated cardiomyopathy (DCM), patient education programs are vital because they provide patients with the information and abilities they need to manage their illness properly. DCM is a chronic, complicated illness that, in order to maximize results and quality of life, calls for constant self-management, lifestyle changes, and adherence to treatment regimens. Patient education initiatives seek to inform people with DCM about their illness, its signs and symptoms, possible side effects, and the significance of taking medications as prescribed, changing one's lifestyle, and getting regular checkups. Through a variety of platforms, such as individual therapy sessions and instructional materials, including booklets and pamphlets, online resources, support groups, and community outreach initiatives, these programs usually offer thorough information about DCM. Furthermore, psychosocial elements of living with DCM may be included in patient education programs, which provide tools and assistance to help patients manage the psychological and emotional effects of their diagnosis.

Restraint Factor for the Dilated Cardiomyopathy Market

Lack of Qualified Specialists Will Limit Market Growth

The lack of qualified specialists is a major obstacle facing the worldwide dilated cardiomyopathy (DCM) industry. The disorder known as DCM is characterized by an enlarged heart muscle, which can result in potentially fatal consequences and diminished cardiac function. As new treatments and improvements in medical technology become available, there is an increasing need for qualified medical personnel who can identify and treat DCM. However, there is a lack of specialists, which impacts patient treatment and research in the sector because the supply has not kept up with the increasing demand. The main cause of the shortage of qualified experts in the worldwide DCM market is the condition's intricacy. Introduction of the Dilated ...

Global Kidney Fibrosis Treatment market size 2025 was XX Million. Kidney Fibrosis Treatment Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

Global Chronic Kidney Disease CKD Drugs market size 2025 was XX Million. Chronic Kidney Disease CKD Drugs Industry compound annual growth rate (CAGR) will be XX% from 2025 till 2033.

As per Cognitive Market Research's latest published report, the Global Liver Fibrosis Treatment market size was USD 14.8 billion in 2022. Liver Fibrosis Treatment Industry's Compound Annual Growth Rate will be 10.9% from 2023 to 2030. Factors Impacting on Liver Fibrosis Treatment Market

The rising prevalence of liver fibrosis across the globe is forecasted to dominate the global liver fibrosis treatment market. In addition, growing healthcare expenditure by increasing funding drives the demand for the global market. Furthermore, growth in the number of research and development activities will provide the opportunity for the growth of the global market. However, the high cost associated with the treatment and the lack of healthcare infrastructure in emerging economies may hamper the growth of the global liver fibrosis treatment market. What is Liver Fibrosis Treatment?

Liver fibrosis is the development of abnormally large amounts of scar tissue in the liver as a result of repeated or continuous liver injury. Fibrosis has asymptomatic but excessive scarring develops cirrhosis, which has symptoms. The severity of the disease is checked by blood and imaging tests, as well as liver biopsy, by medical professionals. Healthcare professionals concentrate on treating the underlying cause of liver fibrosis since this frequently prevents or slows the progression of liver scarring and improves outcomes.